0
Clinical Investigations: SURGERY |

Mitral Valve Repair in Patients With Low Left Ventricular Ejection Fractions*: Early and Late Results

Nirupama G. Talwalkar, MD; Nan R. Earle, MS; Elizabeth Ann Earle, JD; Gerald M. Lawrie, MD, FCCP
Author and Funding Information

*From the The Methodist Hospital, Houston, TX.

Correspondence to: Gerald M. Lawrie, MD, FCCP, 6560 Fannin, Suite 1842, Houston, TX 77030; e-mail: glawrie@TexasSurgical.com



Chest. 2004;126(3):709-715. doi:10.1378/chest.126.3.709
Text Size: A A A
Published online

Study objectives: This retrospective study was performed to examine the outcome of mitral valve repair (ie, mitral valvuloplasty [MVP]) in relation to preoperative low left ventricular ejection fraction (LVEF).

Design and settings: From our series of 338 consecutive patients who underwent MVP between 1983 and 2001, we compared the course of 302 patients with preoperative LVEF of > 35% (group I) to that of 36 patients with LVEF of ≤ 35% (group II).

Results: Preoperatively, group II patients were more likely to be associated with ischemic heart disease (IHD) [p < 0.0002], and to have undergone emergency surgery (p < 0.02) and concomitant coronary artery bypass graft surgery (CABG) [p < 0.02]. The perioperative mortality rate was 8% for group II and 2% for group I (p < 0.03). On multivariate analysis, predictors of increased operative mortality were emergent operation (p < 0.001) and preoperative New York Heart Association (NYHA) class IV (p < 0.02). Predictors of overall mortality (early and late) included emergency operation (p < 0.02), preoperative NYHA class IV (p < 0.002), and IHD (p < 0.0001). Postoperatively, 78% of patients from both groups were in NYHA class I/II. The 5-year rate of freedom from reoperation was 89%. The estimated overall 5-year survival rate (early and late) was 82% for group I and 54% for group II (p < 0.02), and when associated with prior CABG, prior myocardial infarction, or concomitant CABG, it was 0%, 37%, and 63%, respectively, in group II.

Conclusions: Good symptomatic relief and acceptable overall survival can be obtained in patients in both groups after they have undergone MVP, in the absence of serious comorbidities. Preoperative NYHA class IV and end-stage IHD increase early and late mortality, particularly in group II patients, in whom surgery may be a salvage effort only. Prognosis is dismal in group II patients who have previously undergone CABG. In chronic cases, an early referral for MVP electively before deterioration to end-stage heart disease would improve survival even in patients with low LVEF.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543